TABLE 2.
Summary of large-scale SHIV stocksa
| SHIV stock | PBMC utilized | Infectivity titer (TCID50/ml) | Human p27 PBMC (ng/ml) | Viral load (RNA copies/ml) | Rhesus p27 PBMC (ng/ml) | Coreceptor usage |
|---|---|---|---|---|---|---|
| 327c | Human | 5 × 107 | 176.4 | 2.1 × 109 | 3.13 | CCR5 |
| 405c | Human | 2 × 109 | 312.4 | 4.9 × 109 | 0.10 | CCR5 |
| 459c | Human | 1 × 106 | 120.8 | 2.2 × 108 | 0.15 | CCR5 |
| 590c | Human | 1 × 106 | 108.17 | 2.1 × 108 | 0 | CCR5 |
| 823cD6 | Human | 5 × 106 | 87.75 | 2.1 × 109 | 0 | CCR5 |
| 327cRM | Rhesus monkeys | 3 × 106 | 75.53 | 2.2 × 109 | 75.53 | CCR5 |
a
PBMC utilized for stock generation, infectivity in TZM-bl cells (TCID50/ml), SIV p27 levels in human PBMC, viral load (RNA copies/ml), and SIV p27 levels after inoculation of rhesus monkey PBMC and coreceptor usage are shown.